Michael Makris/LinkedIn
Apr 3, 2026, 15:51
Michael Makris: Approved but Unavailable Hemophilia B Gene Therapy Remains Out of Reach
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”If you are hoping to have gene therapy for hemophilia B you will have to wait, as currently there is no product available for use outside China.
Hemgenix is the only FDA/EMA approved gene therapy that is commercially available, but the company making it has announced that they do not have any product due to a manufacturing issue. They stress that this is not a safety issue.
The Chinese product is only approved for use in China, and it is at least theoretically possible to travel to have the infusion in Shanghai.”
Other posts featuring Michael Makris on Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies